Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The goal remains achieving therapeutic objectives while maintaining acceptable quality of life and minimizing adverse effects that could compromise long-term adherence
In the SELECT trial, 17604 adults classified overweight or obesity and established cardiovascular disease, but without diabetes, were randomised to receive semaglutide 2.4 mg weekly or placebo
GLP-1 receptor agonists such as semaglutide work by stimulating the pancreas to release insulin when blood sugar levels rise, while also reducing the levels of glucagon, a hormone that increases blood sugar
Some of the GLP-1RAs are exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide and semaglutide.[5] Despite a plethora of advantages with GLP-1RAs, their usage is limited because of their injectable nature presenting challenges in the initiation and adherence to the use of GLP-1RAs
)
